Partner With Us NRI

Sequent Scientific Ltd share Price Today

Company details

6M Return -7.28%
1Y Return 41.79%
Mkt Cap.(Cr) 2,733.79
Volume 433,721
Div Yield 0.00%
OI Chg %
Volume 433,721

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Sequent Scientific announced Q4FY24 & FY24 results:

  • Highest EBITDA (pre-ESOP cost) in twelve quarters at Rs 411 million; Pre-ESOP cost EBITDA growth of 36% / 221% QoQ / YoY
  • 11.4% EBITDA margin – expanded by 220 / 790 bps QoQ / YoY
  • Q4FY24 Revenue 9.7% QoQ reported ( 7.5% in constant currency ) API business 39% QoQ; FY24 Revenue -3.6% YoY reported
  • Growth for continuing business and post Turkey currency accounting adjustments at 6% YoY reported ( 11% in constant currency) in Q4; FY24 Revenue 1.5% YoY reported

Rajaram Narayanan, MD & CEO, said "It gives me immense satisfaction to share that our transformation program, which began late last year, has continued to deliver according to plan. In Q4FY24, the company achieved its highest EBITDA (pre-ESOP costs) in the last 12 quarters of Rs 411 million. The EBITDA margin for Q4FY24 at 11.4% is in line with our target to exit FY24 with double-digit EBITDA margins. Revenues for the quarter Q4FY24 grew sequentially at 7% in constant currency, and 2% on a reported basis. Adjusting for discontinued business units and currency accounting adjustments in Turkey, our revenues grew 6% YoY in Rs terms and 11.4% in constant currency terms, setting the base for higher growth in the coming year.

I am particularly pleased to share the strong performance delivered by our API business this quarter – 39% sequential increase in API revenues combined with sustained segment margin improvement. This is the outcome of our focus on the quality of business combined with operational excellence initiatives undertaken under Project Pragati. Our stable base of business in regulated markets has allowed us to selectively participate in promising semi-regulated markets witnessing growing volumes. During the quarter, we filed 2 new products, one each in the companion and production animal segments, the commercialization for which too is now expected to pick up. The company has also completed WHO audits and is preparing to get prequalified for WHO supplies.

Despite seasonality factors that affect the Jan-March period, our formulations geographies continued to perform well during Q4FY24, led by strong YoY growth in Europe ( 8%) and India ( 9%). The proactive pricing and portfolio actions in Turkey continue to support margin growth. Some emerging markets in North Africa and Middle East have seen currency issues, delaying execution of a few orders. We are accelerating our initiatives on margin improvement and new business development across all markets. We have already started expanding our footprint in India and should see results from mid-year.

We continue to evaluate inorganic actions for strategic growth in formulations and APIs, to support our operations and emerge as a larger participant in the growing Animal Health industry."

Result PDF

View Other Company Results

Sequent Scientific Ltd shares SWOT Analysis

Strengths (6)

  • Rising Net Cash Flow and Cash from Operating activity
  • Growth in Quarterly Net Profit with increasing Profit Margin (YoY)
  • Company with Zero Promoter Pledge

Weakness (1)

  • Weak Momentum: Price below Short, Medium and Long Term Averages

Opportunity (1)

  • Stock with Low PE (PE < = 10)

Threats (2)

  • Red Flag: Resignation of Top Management
  • RSI indicating price weakness

Resistance and support

R1 111.2
R2 112.9
R3 113.9


S1 108.5
S2 107.5
S3 105.8
Delivery and volume
GRAVITON RESEARCH CAPITAL LLP Bulk Purchase 2024-01-18 134.67 1455783 NSE
GRAVITON RESEARCH CAPITAL LLP Bulk Sell 2024-01-18 134.6 1455783 NSE
GRAVITON RESEARCH CAPITAL LLP Bulk Purchase 2024-01-09 139.01 1292140 NSE
Name Category Shares


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Sequent Scientific Ltd Stocks COMPARISON

Financials( in Cr) Sequent Scientific Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 109.60 1,486.70 1,486.45 4,122.40 1,076.00
% Change -0.50 -0.56 -0.18 0.23 -0.93
Mcap Cr 2,733.79 356,709.13 120,011.07 109,436.94 108,270.78
Revenue TTM Cr 1,420.91 43,885.68 15,790.60 7,767.51 17,237.40
Net Profit TTM Cr -121.98 8,560.84 2,513.47 1,823.38 1,997.30
PE TTM 0.00 35.64 28.16 79.13 28.08
1 Year Return 41.79 59.59 59.76 21.76 112.04
ROCE -3.52 16.79 14.76 19.30 16.25
ROE -9.04 16.46 10.66 14.89 14.05

Equity Capital: 698.78 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 29,248.28 -22,040.96
LAST 3M 102,638.29 -30,717.76
LAST 6M 167,920.74 50,623.85
LAST 12M 262,867.28 126,756.31

Sequent Scientific Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Sequent Scientific Ltd. is a leading manufacturer and exporter of specialized quality formulations aimed at fulfilling the diverse demands of the pharmaceutical industry. It manufactures formulations belonging to the anthelmintic and anti-parasitic segments. It was incorporated in 1985 with its headquarters in Mumbai. During FY 2021-2022, the company’s total revenue was Rs 1,423.66 crore, up 3.92% from the previous financial year, 2020-2021. On 29 August 2022, its market capitalization stood at Rs HYPERLINK "https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/sequentscientific/PID01" 2,788 crore.  

    Sequent Scientific Ltd.’s shares are listed on the Bombay Stock Exchange with the code 512529, and on the National Stock Exchange with the code SEQUENT.  

    Sequent Scientific Ltd. is amongst the top 20 global animal health companies. It is backed by The Carlyle Group, a global investment firm. The company has eight manufacturing facilities across Turkey, Europe, Brazil, and India. The Vizag site in India is the country’s only USFDA-approved dedicated veterinary API facility.  

    The company’s shareholding pattern at the end of the June 2022 quarter showed a promoter stake of 52.79%, foreign institutional investor stake of 6.45%, domestic institutional investor stake of 2.26%, and public stake of 38.1%. The entire promoter share belongs to CA Harbor Investments. During the June 2022 quarter, promoter holdings decreased from 53.02% to 52.79%, mutual fund holdings reduced from 0.30% to 0.29%, and FII holdings increased from 5.84% to 6.45%.  

    Mr Manish Gupta is the company’s managing director and CEO. Its board members include Dr Kamal K Sharma, Mr Sharat Narasapur, Mr Neeraj Bharadwaj, Mr Rahul Mukim, Dr Fabian Kausche, Mr Gregory John Andrews, and Dr (Mrs) Kausalya Santhanam. The auditors of the company are S R B C & Co. LLP. On 30 June 2022, the company had a total of 24.94 crore shares outstanding.  

    On 29 August 2022, the company’s share price closed at Rs 112.50 on BSE and at Rs 111.80 on NSE. The 52-week high for Sequent Scientific Ltd.’s share price was Rs 239.70, and the 52-week low for the company’s share price was Rs 82.  

    The company’s peers include Sun Pharmaceutical Industries Ltd., Divis Laboratories Ltd., Cipla Ltd., and Dr Reddys Laboratories Ltd.  

    As of August 2022, White Oak Capital Flexi Cap Fund had a 0.45% stake in Sequent Scientific Ltd. 

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose 

Registered Address

301 Dosti Pinnacle 3rd Floor, Plot E7 Road No 22 Wagle Indl, Thane, Maharashtra, 400604

Tel : 91-022-41114777
Email : investors:sequent.in
Website : http://www.sequent.in

Adroit Corp. Services Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 512529
Book Closure Date (Month) :
BSE Group : A
ISIN : INE807F01027

FAQ’s on Sequent Scientific Ltd Shares

You can buy Sequent Scientific Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Sequent Scientific Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of May 24, 2024 03:53 PM the closing price of Sequent Scientific Ltd was Rs.109.60.

Market capitalization or market cap is determined by multiplying the current market price of a company�s shares with the total number of shares outstanding. As of May 24, 2024 03:53 PM, the market cap of Sequent Scientific Ltd stood at Rs. 2,733.79.

The latest PE ratio of Sequent Scientific Ltd as of May 24, 2024 03:53 PM is 0.00

The latest PB ratio of Sequent Scientific Ltd as of May 24, 2024 03:53 PM is 0.24

The 52-week high of Sequent Scientific Ltd share price is Rs. 155.50 while the 52-week low is Rs. 71.80

Download App

Download Our App

Play Store App Store
market app